Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -9% unadjusted Improvement Relative Risk Hospitalization time -8% unadjusted c19ivm.org Zubair et al. Ivermectin for COVID-19 LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Retrospective 188 patients in Pakistan (October 2020 - February 2021) Significant confounding by indication likely Zubair et al., Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2022.2062 Favors ivermectin Favors control
The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness
Zubair et al., Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2022.2062
Zubair et al., The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its.., Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2022.2062
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 188 hospitalized patients in Pakistan, 90 treated with ivermectin, showing no significant differences with treatment. The ivermectin group had more severe disease (66% vs 58%, with 6x higher risk for severe disease patients), and more male patients (70% vs. 65%). Higher use of remdesivir and steroids in the ivermectin group also suggests that ivermectin was more likely to be given to patients in more severe condition. There were no side effects seen with ivermectin. Authors note that significantly improved ferritin levels were seen with treatment. Authors state that ivermectin patients received 2 12mg doses, 24 hours apart, but later state that the dosage was not standardized. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; unadjusted results with no group details.
risk of death, 9.0% higher, RR 1.09, p = 1.00, treatment 5 of 90 (5.6%), control 5 of 98 (5.1%), unadjusted.
hospitalization time, 8.0% higher, relative time 1.08, p = 0.40, treatment 90, control 98, unadjusted, Table 3, mean number of days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zubair et al., 18 Jan 2022, retrospective, Pakistan, peer-reviewed, 8 authors, study period October 2020 - February 2021, dosage 12mg single dose.
Contact: muhammad.irfan@aku.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Monaldi Archives for Chest Disease eISSN 2532-5264 https://www.monaldi-archives.org/ Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Monaldi Archives for Chest Disease is, therefore, Epublishing PDF files of an early version of manuscripts that undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one. The final version of the manuscript will then appear on a regular issue of the journal. E-publishing of this PDF file has been approved by the authors. Monaldi Arch Chest Dis 2022 [Online ahead of print] To cite this Article: Zubair SM, Chaudhry MW, Zubairi ABS, et al. The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness. Monaldi Arch Chest Dis doi: 10.4081/monaldi.2022.2062 © the Author(s), 2022 Licensee PAGEPress, Italy Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article. The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness Syed Muhammad Zubair, Muhammad Waleed Chaudhry, Ali Bin Sarwar Zubairi, Talha Shahzad, Aqusa Zahid, Ibrahim Ali Khan, Javaid Ahmed Khan, Muhammad Irfan Section of Pulmonary Medicine, Department of Medicine Aga Khan University Hospital, Karachi, Pakistan Corresponding Author: Muhammad Irfan, Professor, Section of Pulmonary Medicine, Department of Medicine Aga Khan University Hospital, Karachi, Pakistan. Address: Faculty Office Building, National Stadium Road, Aga Khan University Hospital, Karachi, Karachi City, Sindh 74800. Phone: 02134864664 - Cell phone: +923002111459 Email: muhammad.irfan@aku.edu Acknowledgments: None i) Authors Contribution: 1) Syed Muhammad Zubair: Data Collection, statistical analysis, literature review, manuscript writing. 2) Muhammad Waleed Chaudhry: Data Collection, statistical analysis, literature review, manuscript writing. 3) Ali Bin Sarwar Zubairi: Wrote, reviewed and edited the manuscript. 4) Talha Shahzad: Reviewed and edited the manuscript. 5) Aqusa Zahid: Data Collection, reviewed and edited the manuscript. 6) Ibrahim Ali Khan: Reviewed and edited the manuscript. 7) Javaid Ahmed Khan: Reviewed and edited the manuscript. 8) Muhammad Irfan: Conceived the idea, wrote, reviewed and edited the manuscript. Ethics approval: The study protocol was approved by the Ethics Review Committee (ERC) of the Aga Khan University Hospital (Application no: 2021-5902-16610). ii) There is no conflict of interests. iii) There is no funding for this article. The abstract of this article has been scheduled to be presented at the following forum: 1) Abstract title: Role of ivermectin in hospitalized patients with mild to moderate COVID-19. To be presented as an ‘e-poster’ at virtual European Respiratory Society Congress 2021 on 07-09-2021. Abstract The COVID-19 pandemic has led to mortality and morbidity since December 2019. Many possible treatment options have been advised till date. The role of ivermectin in the treatment of COVID19 disease remains controversial. The aim of our study was to evaluate the effect of ivermectin in hospitalized patients with non-severe and severe..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit